Senzime
Senzime announces full subscription of 117 MSEK directed share issue
Senzime AB (publ) (“Senzime” or the “Company”) announced on 25 September 2023 the board of directors’ resolution to carry out a directed share issue of 18,000,000 shares at subscription price SEK 6.50 per share (the ”Share Issue”). The subscribers in the Share Issue consisted of a number of well-established new investors (Segulah Medical Acceleration and Carnegie Fonder), as well as a few existing shareholders with a long term interest for the Company (Fjärde AP-fonden, Crafoordska stiftelsen, Handelsbanken Fonder, Fredrik Rapp and Swedbank Robur). The Share Issue was subject to approval from a general meeting, and such approval – which was unanimous – was obtained on the extraordinary general meeting held on 19 October 2023. Subscription and allotment of all the issued shares have now been finalized.
Through the Share Issue, the number of shares in the Company is increased from 100,122,614 to 118,122,614 shares. The share capital of the Company is increased by SEK 2,250,000, from SEK 12,515,326.75 to SEK 14,765,326.75. The Swedish Financial Supervisory Authority is currently processing a prospectus regarding admittance to trading. The new shares will be admitted to trading on Nasdaq Stockholm as soon as approval has been obtained from the Authority, which is estimated to 9 November 2023.
Advisers
In connection with the Share Issue, the Company has retained Zonda Partners as financial advisor and Advokatfirman Lindahl KB as legal adviser to the Company.
Datum | 2023-10-24, kl 20:30 |
Källa | MFN |
![](https://static.allaaktier.se/ads/hand-waving-2.png)